Continued treatment for cancer patients from earlier Roche studies
Continues Roche cancer medicines for people still on treatment from an earlier study.
Key facts
- Who runs it
- Hoffmann-La Roche
- Where
- Goyang-si, Gyeonggi-do, Seongnam-si, and Seoul, South KoreaSee the 5 sitesAlso in 14 other countries, 78 sites
- Registry title
- A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 200 people, planned
- Started
- 1 Jun 2023
- Expected to end
- 1 Mar 2033
- Type of study
- Interventional, 2 groups
- Treatments tested
- Ipatasertib
- Tiragolumab
- Atezolizumab
- Tiragolumab and Atezolizumab
- Bevacizumab
- Entrectinib
- Inavolisib
- Divarasib
- Giredestrant
- Record updated
- 6 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with cancer who are still on treatment in a Genentech or Roche study and cannot get that treatment locally.
- Sex
- All sexes can join.
- Earlier treatment
- Must be taking the Roche study drug or the comparator drug in the parent study. The first dose here must come within 7 days of the treatment break allowed by that study.
Main reasons for not taking part
- Meets any of the stopping rules of the parent study at enrolment
- The treatment is sold in the person's country for their disease and they can get it
- Took other anti-cancer treatment between the parent study and this study, apart from what the parent study allowed
- Stopped all study treatment for any reason in or after the parent study
- Serious side effects not yet resolved to baseline or Grade 1 or lower, unless the investigator judges the person stable and the benefit greater than the risk
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Eligible for continuing Roche IMP-based therapy at the time of roll-over from the parent study, as per the parent study protocol OR
- Eligible for continuing the comparator agent(s) in a Genentech- or Roche-sponsored study as per the parent study protocol, with no access to commercially available comparator agent
- First dose of study treatment in this extension study will be received within 7 days of the treatment interruption window allowed by the parent study
- Continue to benefit from the Roche IMP-based therapy or comparator at the time of roll-over from the parent study as assessed by the investigator
- Ability to comply with the extension study protocol, per Investigator's judgement
Who cannot take part
- Treatment with any anti-cancer treatment (other than treatment permitted in the parent study) during the time between last treatment in the parent study and the first dose of study treatment in this extension study
- Concurrent participation in any therapeutic clinical trial (other than the parent study)
- Study treatment or comparator agent is commercially marketed in the participant's country for the participant-specific disease and is accessible to the participant
- Meet any of the study treatment discontinuation criteria specified in the parent study at the time of enrollment in this extension study
- Permanent discontinuation of all study treatment(s) or comparator agent(s) for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in this extension study (if applicable)
- Ongoing SAE(s) that has not resolved to baseline level or Grade ≤1 from the parent study or during the time between the last treatment in the parent study and the first dose of study treatment in this extension study. Potential participants with an ongoing SAE that has not resolved to baseline level or Grade 1 may be enrolled at the investigator's discretion, provided the event is deemed clinically stable and the investigator documents that the potential clinical benefit outweighs the risk to the potential participant
Where in South Korea
Also in 14 other countries, 78 sites
- National Cancer CenterGoyang-si, South KoreaTaking people
- CHA Bundang Medical CenterGyeonggi-do, South KoreaTaking people
- Seoul National University Bundang HospitalSeongnam-si, South KoreaNo longer taking part
- Samsung Medical CenterSeoul, South KoreaTaking people
- Asan Medical CenterSeoul, South KoreaNo longer taking part
About the trial
What the trial wants to find out
The purpose of this extension study is to provide continued treatment with Roche investigational medicinal product (IMP[s]) monotherapy or Roche IMP(s) combined with other agent(s) or comparator agent(s) for eligible participants with cancer who are still on study treatment at the time of roll-over from the parent study and who do not have access to the study treatment locally.
The 2 groups in the trial
- Roche IMP(s) MonotherapyTreatment being tested
Participants will continue to receive Roche IMP(s) monotherapy as per parent protocol, until disease progression, loss of clinical benefit as judged by the investigator, death, withdrawal of study consent, unacceptable toxicity, pregnancy, participants non-compliance, if local access becomes available or study termination by the Sponsor, whichever occurs first.
Treatment: Ipatasertib, Atezolizumab, Bevacizumab, Entrectinib, Inavolisib, Divarasib, and Giredestrant
- Roche Combined AgentsTreatment being tested
Participants will continue to receive Roche IMP(s) in combination with other agent(s) as per parent protocol, until disease progression, loss of clinical benefit as judged by the investigator, death, withdrawal of study consent, unacceptable toxicity, pregnancy, participants non-compliance, if local access becomes available or study termination by the Sponsor, whichever occurs first.
Treatment: Tiragolumab, Atezolizumab, Tiragolumab and Atezolizumab, Bevacizumab, Inavolisib, Divarasib, and Giredestrant
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- An Open-Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Study
- Plain-language title
- Continued treatment for cancer patients from earlier Roche studiesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 6 November 2026